Systemic Scleroderma
32
5
7
15
Key Insights
Highlights
Success Rate
79% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
12.5%
4 terminated out of 32 trials
78.9%
-7.6% vs benchmark
9%
3 trials in Phase 3/4
47%
7 of 15 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 15 completed trials
Clinical Trials (32)
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Clinical Study of Divozilimab in Patients With Systemic Scleroderma
Sildenafil Effect on Digital Ulcer Healing in sClerodErma SEDUCE STUDY
Microparticles's Role in the Pathophysiology of Systemic Lupus Erythematosus and Systemic Sclerosis
Efficacy and Safety of Firsekibart in the Treatment of Systemic Sclerosis
TBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis
Effects of a Personalized Standardized Rehabilitation Program in Systemic Sclerosis
Familial Systemic Scleroderma
Diffuse Cutaneous Scleroderma (DSSc) SFDI Study
Longitudinal Spatial Frequency Domain Imaging Study
Efficacy and Safety of Allogenic Cultured Adipose-derived Mesenchymal Stromal Cell Injections on MoUth Fibrosis and Handicap in Patients With Systemic sclEroderma
Role of Eosinophil in Fibrogenesis of Systemic Sclerosis
Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune Deficiencies
Scleroderma Treatment With Autologous Transplant (STAT) Study
Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells
Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung Disease
Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease
Clinical and Paraclinical Characteristics of the Systemic Scleroderma Cohort According to the Criteria ACR 2013 and the History of Professional Exposure or of Agricultural Environment
Evaluation of the Serum Soluble Fractalkine as a Biomarker of Pulmonary Fibrosis in Systemic Sclerosis
Cardiac Repercussion of Systemic Sclerodermias